{"organizations": [], "uuid": "d8464f20c59abe3da723111045f816d26990ac15", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bluebird-bio-expects-three-regulat/brief-bluebird-bio-expects-three-regulatory-filings-by-end-2019-idUSL1N1P40T0", "country": "US", "domain_rank": 408, "title": "BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T18:28:00.000+02:00", "replies_count": 0, "uuid": "d8464f20c59abe3da723111045f816d26990ac15"}, "author": "", "url": "https://www.reuters.com/article/brief-bluebird-bio-expects-three-regulat/brief-bluebird-bio-expects-three-regulatory-filings-by-end-2019-idUSL1N1P40T0", "ord_in_thread": 0, "title": "BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019", "locations": [], "entities": {"persons": [{"name": "bill berkrot", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "eu", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "bluebird bio inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 9, 2018 / 4:30 PM / Updated 39 minutes ago BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019 Reuters Staff \nJan 9 (Reuters) - Bluebird Bio Inc: \n* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019 \n* BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018 \n* BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)", "external_links": [], "published": "2018-01-09T18:28:00.000+02:00", "crawled": "2018-01-09T18:47:19.004+02:00", "highlightTitle": ""}